Rodriguez Susan has filed 15 insider transactions across 5 companies since January 2024.
Most recent transaction: a grant/award of 48728 shares of Monopar Therapeutics ($MNPR) on March 02, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 2, 2026 | Monopar Therapeutics | $MNPR | Rodriguez Susan | CCSO | A | Stock Options | 48728 | $0.00 | 48,728.0000 | 6,662,930 | 9999.99% | 0.73% |
| Feb. 12, 2026 | AVADEL PHARMACEUTICALS PLC | $AVDL | Rodriguez Susan | Chief Operating Officer | D | Stock Option (Right to Buy) | 300000 | $0.00 | 0.0000 | 101,276,000 | 100.00% | 0.30% |
| June 2, 2025 | Veradigm Inc. | $MDRX | Rodriguez Susan | Not found | A | Common Stock | 46512 | $4.30 | 88,618.0000 | 112,079,000 | 110.46% | 0.04% |
| May 13, 2025 | AVADEL PHARMACEUTICALS PLC | $AVDL | Rodriguez Susan | Chief Operating Officer | A | Stock Option (Right to Buy) | 300000 | $0.00 | 300,000.0000 | 95,141,000 | 9999.99% | 0.32% |
| Jan. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Not found | A | Common Stock | 17950 | $0.00 | 87,180.0000 | 0 | 25.93% | 0.00% |
| Jan. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Not found | A | Stock Option (Right to Buy) | 35900 | $0.00 | 35,900.0000 | 0 | 9999.99% | 0.00% |
| Jan. 30, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Not found | A | Common Stock | 17950 | $0.00 | 87,180.0000 | 0 | 25.93% | 0.00% |
| Jan. 30, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Not found | A | Stock Option (Right to Buy) | 35900 | $1.73 | 35,900.0000 | 0 | 9999.99% | 0.00% |
| May 31, 2024 | Veradigm Inc. | $MDRX | Rodriguez Susan | Not found | A | Common Stock | 42106 | $0.00 | 42,106.0000 | 112,079,000 | 9999.99% | 0.04% |
| May 21, 2024 | ARDELYX, INC. | $ARDX | Rodriguez Susan | Chief Commercial Officer | S | Common Stock | 6703 | $7.81 | 449,092.0000 | 0 | 1.47% | 0.00% |
| Feb. 20, 2024 | ARDELYX, INC. | $ARDX | Rodriguez Susan | Chief Commercial Officer | S | Common Stock | 6928 | $8.75 | 452,795.0000 | 0 | 1.51% | 0.00% |
| Jan. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Director | A | Stock Option (Right to Buy) | 83685 | $0.00 | 83,685.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Rodriguez Susan | Director | A | Common Stock | 13948 | $0.00 | 69,230.0000 | 0 | 25.23% | 0.00% |
| Jan. 16, 2024 | ARDELYX, INC. | $ARDX | Rodriguez Susan | Chief Commercial Officer | A | Stock Option (Right to Buy) | 145000 | $0.00 | 145,000.0000 | 0 | 9999.99% | 0.00% |
| Jan. 16, 2024 | ARDELYX, INC. | $ARDX | Rodriguez Susan | Chief Commercial Officer | A | Common Stock | 112750 | $0.00 | 459,723.0000 | 0 | 32.50% | 0.00% |